• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在抗肿瘤治疗中靶向细胞周期蛋白依赖性激酶。

Targeting cyclin-dependent kinases in anti-neoplastic therapy.

机构信息

ManRos Therapeutics, Centre de Perharidy, 29680 Roscoff, France.

出版信息

Curr Opin Cell Biol. 2013 Dec;25(6):772-9. doi: 10.1016/j.ceb.2013.08.004. Epub 2013 Sep 6.

DOI:10.1016/j.ceb.2013.08.004
PMID:24011867
Abstract

Cell cycle progression is controlled by sequential activation of cyclin-dependent kinases (CDKs), which are often deregulated in cancer. Consequently numerous pharmacological inhibitors of CDKs have been developed with the aim of treating cancers. The article briefly reviews CDK inhibitors and their use to treat cancers, with specific focus on the use of biomarkers and drugs combination to improve their therapeutic efficacy.

摘要

细胞周期的进展受细胞周期蛋白依赖性激酶（CDKs）的顺序激活控制，而 CDK 在癌症中经常失调。因此，已经开发了许多 CDK 的药理学抑制剂，旨在治疗癌症。本文简要综述了 CDK 抑制剂及其在癌症治疗中的应用，特别关注了使用生物标志物和药物联合来提高其治疗效果。

相似文献

1
Targeting cyclin-dependent kinases in anti-neoplastic therapy.在抗肿瘤治疗中靶向细胞周期蛋白依赖性激酶。
Curr Opin Cell Biol. 2013 Dec;25(6):772-9. doi: 10.1016/j.ceb.2013.08.004. Epub 2013 Sep 6.
2
Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).靶向细胞周期蛋白依赖性激酶治疗癌症的研究性药物：近期研究结果（2013 - 2016年）更新
Expert Opin Investig Drugs. 2016 Oct;25(10):1215-30. doi: 10.1080/13543784.2016.1234603.
3
Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.细胞周期蛋白依赖性激酶抑制剂的双重作用：靶向细胞周期进程并激活野生型p53蛋白。
Expert Opin Investig Drugs. 2006 Jan;15(1):23-38. doi: 10.1517/13543784.15.1.23.
4
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.靶向人类癌症中的细胞周期蛋白依赖性激酶与细胞周期进程
Semin Oncol. 2015 Dec;42(6):788-800. doi: 10.1053/j.seminoncol.2015.09.024. Epub 2015 Sep 24.
5
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.细胞周期蛋白依赖性蛋白激酶抑制剂包括帕博西尼作为抗癌药物。
Pharmacol Res. 2016 May;107:249-275. doi: 10.1016/j.phrs.2016.03.012. Epub 2016 Mar 16.
6
Cyclin-dependent kinase modulators and cancer therapy.细胞周期蛋白依赖性激酶调节剂与癌症治疗。
BioDrugs. 2012 Dec 1;26(6):377-91. doi: 10.1007/BF03261895.
7
The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.细胞周期蛋白依赖性激酶（CDKs）在肉瘤中的作用及治疗潜力。
Cancer Metastasis Rev. 2016 Jun;35(2):151-63. doi: 10.1007/s10555-015-9601-1.
8
An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.深入了解细胞周期蛋白依赖性激酶抑制剂作为治疗晚期癌症的潜在治疗药物的新兴作用。
Biomed Pharmacother. 2018 Nov;107:1326-1341. doi: 10.1016/j.biopha.2018.08.116. Epub 2018 Aug 29.
9
Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.细胞周期蛋白依赖性激酶抑制：靶向蛋白-蛋白相互作用的机会。
Adv Protein Chem Struct Biol. 2020;121:115-141. doi: 10.1016/bs.apcsb.2019.11.009. Epub 2019 Dec 18.
10
Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.药理学上的细胞周期蛋白依赖性激酶抑制剂：对结直肠癌的影响。
World J Gastroenterol. 2016 Feb 21;22(7):2159-64. doi: 10.3748/wjg.v22.i7.2159.

引用本文的文献

1
Binding Mechanism of Inhibitors to CDK6 Deciphered by Multiple Independent Molecular Dynamics Simulations and Free Energy Predictions.通过多独立分子动力学模拟和自由能预测解析抑制剂与CDK6的结合机制
Molecules. 2025 Feb 20;30(5):979. doi: 10.3390/molecules30050979.
2
Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs).新型meriolin衍生物通过抑制细胞周期蛋白依赖性激酶（CDK），有效抑制白血病和淋巴瘤细胞的细胞周期进程和转录。
Cell Death Discov. 2024 Jun 11;10(1):279. doi: 10.1038/s41420-024-02056-6.
3
Novel tetrahydroisoquinolines as DHFR and CDK2 inhibitors: synthesis, characterization, anticancer activity and antioxidant properties.
新型四氢异喹啉类化合物作为二氢叶酸还原酶和细胞周期蛋白依赖性激酶2抑制剂：合成、表征、抗癌活性及抗氧化性能
BMC Chem. 2024 Feb 16;18(1):34. doi: 10.1186/s13065-024-01139-w.
4
Research progress of anticancer drugs targeting CDK12.靶向细胞周期蛋白依赖性激酶12的抗癌药物研究进展
RSC Med Chem. 2023 May 23;14(9):1629-1644. doi: 10.1039/d3md00004d. eCollection 2023 Sep 19.
5
New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches.具有CDK9抑制活性的新型咪唑并吡嗪类化合物作为抗癌和抗病毒药物：合成、计算机模拟及体外评估方法
Pharmaceuticals (Basel). 2023 Jul 18;16(7):1018. doi: 10.3390/ph16071018.
6
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.靶向小儿肿瘤学中被劫持的激酶信号通路：机遇与现状
Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664.
7
Shining Light on Protein Kinase Biomarkers with Fluorescent Peptide Biosensors.利用荧光肽生物传感器揭示蛋白激酶生物标志物
Life (Basel). 2022 Mar 31;12(4):516. doi: 10.3390/life12040516.
8
Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation.靶向CDK5激酶活性和胶质母细胞瘤细胞增殖的喹唑啉酮类似物的鉴定
Front Chem. 2020 Aug 19;8:691. doi: 10.3389/fchem.2020.00691. eCollection 2020.
9
Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.靶向 CDK4/ Cyclin D 界面的订书肽与 Abemaciclib 联合抑制 KRAS 突变型肺癌生长。
Theranostics. 2020 Jan 12;10(5):2008-2028. doi: 10.7150/thno.40971. eCollection 2020.
10
R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy.R-罗哌卡因改善脊髓性肌萎缩小鼠模型中的运动神经元功能。
iScience. 2020 Feb 21;23(2):100826. doi: 10.1016/j.isci.2020.100826. Epub 2020 Jan 10.